Gyre Therapeutics (NASDAQ: GYRE) revenue
Gyre Therapeutics reported revenue of $116.6m for fiscal 2025, 10.2% more than in fiscal 2024 ($105.8m). Since fiscal 2017 its revenue has grown by 11,352.7%, an average growth of 80.9% a year.
Fiscal 2025 is the highest of the 8 fiscal years on record for Gyre Therapeutics. The biggest drop was in fiscal 2018, −99.4%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $116.6m | +10.2% | $11.5m | 9.9% |
| 2024 | $105.8m | −6.8% | $16.2m | 15.3% |
| 2023 | $113.5m | +10.9% | −$67.2m | −59.3% |
| 2022 | $102.3m | +1,294.0% | $9.2m | 9.0% |
| 2021 | $7.3m | −65.0% | −$87.9m | −1,197.8% |
| 2020 | $20.9m | — | −$57.4m | −273.9% |
| 2018 | $0.0m | −99.4% | −$33.8m | −563,700.0% |
| 2017 | $1.0m | — | −$21.8m | −2,143.6% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Gyre Therapeutics revenue compared with its sector
By revenue for its latest fiscal year, Gyre Therapeutics ranks 275th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Gyre Therapeutics, 10.2%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 273rd | Xencor | $125.6m | 13.7% |
| 274th | Monte Rosa Therapeutics | $123.7m | 63.5% |
| 275th | Gyre Therapeutics | $116.6m | 10.2% |
| 276th | OraSure Technologies | $115.0m | −38.1% |
| 277th | Agenus | $114.2m | 10.4% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of Gyre Therapeutics
- How much revenue did Gyre Therapeutics make in fiscal 2025?
- Gyre Therapeutics reported revenue of $116.6m for fiscal 2025, compared with $105.8m in fiscal 2024.
- How much has the revenue of Gyre Therapeutics grown?
- Between fiscal 2017 and fiscal 2025 it went from $1.0m to $116.6m: 11,352.7% more, an average growth of 80.9% a year.
- What was the best year for revenue at Gyre Therapeutics?
- Of its last 8 fiscal years, fiscal 2025, with $116.6m.
- Where does Gyre Therapeutics rank in its sector by revenue?
- It ranks 275th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Gyre Therapeutics come from?
- From the annual report (Form 10-K) that Gyre Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Gyre Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2018 · 2017. More on Gyre Therapeutics: the Gyre Therapeutics page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.